In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics (NASDAQ: HTGM), with a price target of $7. The company’s shares closed yesterday at $3.46.
Selvaraju wrote:
“Our price target is derived from a market value of the firm at $200M, which includes a discounted cash flow analysis based asset value of $210M for the HTG EdgeSeq platform, and excludes $10M projected debt, with a 15% discount rate and 0% terminal growth rate.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -7.8% and a 28.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on HTG Molecular Diagnostics is a Strong Buy with an average price target of $6.75, which is a 95.1% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $7 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.83 and a one-year low of $1.71. Currently, HTG Molecular Diagnostics has an average volume of 685.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
